Beigene (NASDAQ:ONC) Shares Gap Up - Time to Buy?

Beigene, Ltd. (NASDAQ:ONC - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $250.92, but opened at $264.02. Beigene shares last traded at $264.23, with a volume of 155,764 shares changing hands.

Wall Street Analysts Forecast Growth

ONC has been the subject of several research analyst reports. Sanford C. Bernstein set a $259.00 target price on Beigene in a research report on Thursday, March 13th. Macquarie boosted their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and raised their target price for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. Guggenheim reissued a "buy" rating on shares of Beigene in a report on Friday, February 28th. Finally, JMP Securities set a $348.00 price target on Beigene in a research note on Friday, February 28th.

Beigene Trading Down 0.5 %

The stock has a market cap of $26.25 billion, a PE ratio of -32.30, a P/E/G ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. On average, equities analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Insider Activity at Beigene

In related news, insider Xiaodong Wang sold 8,146 shares of Beigene stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68. Following the sale, the insider now owns 5,240,882 shares of the company's stock, valued at approximately $1,334,223,739.56. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Oyler sold 101,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $244.30, for a total value of $24,674,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,052,367 shares of company stock worth $270,454,249. 7.43% of the stock is owned by company insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.